| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
21 |
27 |
56 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Director |
– • – |
2024-01-08 |
4 |
A |
$99.05 |
$4,953 |
D/D |
50 |
425,162 |
|
- |
|
| Bodem Barbara W. |
Director |
– • – |
2023-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,180 |
2,180 |
|
- |
|
| Countouriotis Athena |
Director |
– • – |
2023-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,180 |
2,180 |
|
- |
|
| Enyedy Mark J |
Director |
– • – |
2023-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,180 |
2,180 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2023-12-21 |
4 |
AS |
$93.99 |
$939,900 |
D/D |
(10,000) |
425,112 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2023-12-21 |
4 |
OE |
$63.10 |
$631,000 |
D/D |
10,000 |
435,112 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2023-12-13 |
4 |
AS |
$95.30 |
$1,311,709 |
D/D |
(13,764) |
55,710 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2023-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,370 |
425,112 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2023-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
17,750 |
194,254 |
|
- |
|
| Hardy Alexander |
Chief Executive Officer |
• • – |
2023-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
115,371 |
115,371 |
|
- |
|
| Guyer Charles Greg |
EVP, Chief Technical Officer |
• – – |
2023-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,840 |
52,014 |
|
- |
|
| Guyer Charles Greg |
EVP, Chief Technical Officer |
• – – |
2023-10-31 |
4 |
A |
$69.23 |
$9,208 |
D/D |
133 |
40,174 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2023-10-04 |
4 |
A |
$85.57 |
$856 |
D/D |
10 |
422,742 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2023-08-16 |
4 |
AS |
$90.00 |
$450,000 |
D/D |
(5,000) |
60,804 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2023-08-10 |
4 |
S |
$90.43 |
$1,085,111 |
D/D |
(12,000) |
176,187 |
|
- |
|
| Guyer Charles Greg |
EVP, Chief Technical Officer |
• – – |
2023-08-09 |
4 |
S |
$93.30 |
$500,109 |
D/D |
(5,360) |
40,041 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2023-08-08 |
4 |
S |
$89.42 |
$983,662 |
D/D |
(11,000) |
69,474 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-08-08 |
4 |
S |
$88.29 |
$529,740 |
D/D |
(6,000) |
422,732 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-08-07 |
4 |
S |
$88.10 |
$352,400 |
D/D |
(4,000) |
428,732 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2023-06-29 |
4 |
D |
$88.93 |
$869,735 |
D/D |
(9,780) |
45,805 |
|
- |
|
| Hombach Robert J. |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
30,500 |
|
- |
|
| Ho Maykin |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
16,640 |
|
- |
|
| Slamon Dennis |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
30,809 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
33,140 |
|
- |
|
| Anderson Elizabeth M |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
23,080 |
|
- |
|
2582 Records found
|
|
Page 4 of 104 |
|
|
1.44 (1.6%) 
